NCT04691388View on ClinicalTrials.gov

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

September 4, 2024

Study Completion Date

December 1, 2024

Conditions
NSCLC
Interventions
DRUG

sintilimab combined with anlotinib

All patients will receive sintilimab combined with anlotinib every 3 weeks

Trial Locations (1)

310022

Zhejiang Cancer Hospital, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Zhejiang Cancer Hospital

OTHER